Full-Time
Analyst – Medical Economics & Analytics
Posted on 1/15/2026
Progyny
501-1,000 employees
Fertility benefits management for employers
Compensation Overview
$70k - $90k/yr
No H1B Sponsorship
New York, NY, USA
Hybrid
Three days per week in the office.
 Business & Strategy (1) |
|---|
- 1-3 years of relevant experience, preferably at a top-tier consulting firm or healthcare company
- Bachelor’s degree required
- Enjoys analyzing large sets of data (30M+ rows)
- Proficiency in Excel required
- Proficiency in SQL required
- Prior experience with data visualization tools (e.g. Power BI, Cognos, Tableau, Looker) preferred
- Organized and methodical with strong attention to detail
- Demonstrated ability to be adaptive and inquisitive; natural problem solver
- Ability to work autonomously with minimal direction on multiple endeavors at once
- Driven to deliver results with the ability to establish rapport, earn trust, and effectively collaborate with others
- Become a subject matter expert (SME) in all data related to our members, users, clients and clinics, including scheduled appointments, member interactions, treatment outcomes, contracted rates and member claims
- Develop mastery in Excel, SQL and PowerBI to support analysis and operations of your stakeholder’s key initiatives
- Create dashboards and regular reporting to track project impact on KPIs; celebrate successes and identify & address failures
- Identify opportunities for product, operational, or strategic improvements and communicate ideas to leadership
- Drive cross departmental collaboration by creating operational project plans and managing stakeholders across teams including any of the following: Member and Provider Services, Product, Marketing, Data Engineering, Client Success and Network Management teams
- Support in the presentation of insights to key stakeholders (including VPs, C-suite and external physicians and data teams from Progyny’s vast network of partners)
Progyny is a fertility benefits manager that partners with employers to offer comprehensive fertility and family-building services to employees. It provides a wide range of services including IUI, IVF, fertility preservation, adoption assistance, and surrogacy support, all integrated into employers’ existing benefits packages. The company makes money by signing contracts with employers, typically using a fixed-fee or per-employee-per-month pricing model, and it works to deliver better clinical outcomes to reduce overall treatment costs. Unlike broader health insurers, Progyny focuses specifically on fertility care and family-building, emphasizing measurable clinical results and seamless workflow within the benefits ecosystem. Its goal is to expand access to inclusive fertility benefits while improving outcomes and controlling costs for employers and employees.
Company Size
501-1,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
2008
Simplify's Take
What believers are saying
- Progyny Select targets 50M small-business employees starting 2027 with fixed PEPM pricing.
- Early cycle-aware education shortened time-to-pregnancy by 42%, improving member retention.
- Wins majority of competitive deals with no increased competition observed in 2026.
What critics are saying
- Large client non-renewals reduced Q1 2026 growth to 1.4% YoY excluding one account.
- Stock down 32% YTD after missing Q1 guidance by 5.1%, eroding investor confidence.
- Fortune 500 concentration exposes 595 clients to mass non-renewals during 2026-2027 cycles.
What makes Progyny unique
- 1,000+ vetted specialists network with 72% lower multiples incidence versus competitors.
- SmartCycle bundled model replaces lifetime caps, enabling full-course fertility treatment.
- Data-driven platform forecasts employer costs and measures outcomes with 1.03-1.09% stable utilization.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Company Equity
401(k) Retirement Plan
401(k) Company Match
Performance Bonus
Family Planning Benefits
Fertility Treatment Support
Wellness Program
Mental Health Support
Company Social Events
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Progyny CEO Pete Anevski outlined the company's utilization forecasting and the rollout of its fully insured product, Progyny Select, during a KeyBanc conference. He said the company focuses on actual benefit use rather than eligible lives counts, noting utilization has remained stable at approximately 1.03% to 1.09%. Anevski explained that Q1 consultations typically drive higher-revenue treatment activity in Q2 through Q4. The company forecasts using client history, industry patterns and where members are in their fertility journey. Progyny Select will target small-group employers through brokers and professional employer organisations, covering IVF only with lifetime caps and annual repricing to manage risk. Commercialisation begins now, but the product is expected to go live in 2027. Anevski said recent selling seasons showed no increased competition, with Progyny continuing to win "the majority of the time" against competitors.
Progyny to participate in inaugural HHS Women's Health conference. Company's Chief Medical Officer to present new fertility research that shows value of personalized care and treatment guidance for improving outcomes NEW YORK, March 11, 2026 - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that Chief Medical Officer Janet Choi, MD, will present new fertility research during the first annual Health and Human Services (HHS) National Conference on Women's Health, March 11-13, 2026, in Washington, DC. The event will bring together leaders across the industry to explore breakthroughs in research, prevention, diagnosis, and treatment of health conditions that affect women across the lifespan. Progyny's participation in the conference represents the company's role in contributing to and helping shape the national conversation on advancing women's health. As a recognized leader in fertility, family building, and women's health benefits, Progyny has spent the past decade partnering with employers, health plans, and clinical leaders to elevate the standard of care, improve outcomes for women and families, and advance innovation. The company has one of the largest data sets on fertility in the U.S., providing a unique ability to gather insights that can improve health outcomes. The fertility research being presented, co-authored by Alan Copperman, MD, Managing Director and CEO of RMA of New York, assessed how integrated education and clinician-guided decision-making influence treatment selection, timing, clinical outcomes, and cost of care. Key findings include: * Early cycle awareness can support informed decision-making: Nearly half of women who received early cycle-aware education did not pursue fertility treatment. * Personalized fertility care can help patients reach pregnancy more efficiently, limiting the emotional and physical toll: In this member population - where benefit design did not mandate step-protocol requirements - time to achieve a successful pregnancy in days was up to 42% shorter. * Age remains an important factor in fertility treatment success: In this analysis, only approximately 8% of IUI (intrauterine insemination) cycles were successful among patients age 35 and over, reinforcing the importance of timely evaluation and individualized care planning. * Individualized treatment decisions may help optimize birth outcomes and cost: Treatment pathways should consider the risk of multiples which can increase the likelihood of neonatal intensive care needs and associated costs. "Fertility care is highly personal and time-sensitive, and treatment decisions should reflect each patient's clinical circumstances. These findings underscore the value of personalized, clinician-guided care in helping patients make informed decisions about their family building journey," said Janet Choi, MD, Chief Medical Officer, Progyny. "The selection of Progyny's fertility research for presentation at this national forum highlights the relevance of evaluating how fertility care pathways affect patient experience and outcomes." About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. Progyny Inc. envision a world where everyone can realize their dreams of family and ideal health. Its outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Its benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact:
Progyny shares fell 22% after the fertility benefits company issued weak guidance for 2026, overshadowing strong fourth-quarter results. First-quarter 2026 revenue guidance of $325.5 million missed Wall Street expectations by 5.1%, whilst full-year adjusted earnings per share and EBITDA forecasts also disappointed analysts. Despite reporting fourth-quarter 2025 revenue of $318.4 million—up 6.7% year-on-year and beating expectations—and adjusted earnings per share of $0.48 that exceeded consensus by nearly 20%, investors focused on the weaker outlook, signalling concerns about future growth. The stock is down 32.1% year-to-date and trading 38.5% below its 52-week high of $28.42. Shares closed at $17.47.
Progyny, a fertility benefits provider, reported strong fourth-quarter results for 2025, with annual revenue reaching $1.29 billion and adjusted EBITDA of $222 million, both exceeding guidance by $90 million and $28 million respectively. The company generated record operating cash flow of $210 million, up 17% year-over-year. CEO Pete Anevski noted that 2025 marked the fourth consecutive quarter where revenue and adjusted EBITDA surpassed expectations. Both metrics grew double digits compared to 2024. The company provided financial outlook for 2026 during the earnings call, including anticipated client numbers, covered lives, and utilization rates. Progyny's management discussed the demand for its fertility and family-building solutions and its strategy for acquiring new clients whilst retaining existing ones.
Progyny, a New York-based provider of fertility and family building benefits, reported fourth-quarter earnings of $12.5 million, or 48 cents per share on an adjusted basis, surpassing Wall Street expectations of 38 cents per share. Revenue reached $318.4 million, exceeding analyst forecasts of $303.9 million. For the full year, the company posted profit of $58.5 million on revenue of $1.29 billion. Progyny expects first-quarter revenue between $319 million and $332 million, with earnings per share of 42 to 45 cents. The company projects full-year revenue of $1.36 billion to $1.41 billion, with earnings per share ranging from $1.83 to $1.95.